compound introduction
aldemedine 是一种 μ-阿片受体拮抗剂 (PAMORA)。Naldemedine 对重组人源 μ-、δ- 和 κ- 阿片受体表现出强大的亲和作用 (Ki 分别为 0.34，0.43，0.94 nM) 和拮抗作用 (IC50 分别为 25.57，7.09，16.1 nM) 。Naldemedine 可用于阿片类化合物引起的便秘 (OIC) 研究。Naldemedine 预测可能与 SARS-CoV2 基因组编码的 3CLpro 结合。 Naldemedine is a μ-opioid receptor antagonist (PAMORA)[1]. Naldemedine shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors. Naldemedine can be used in opioid-induced constipation (OIC) research. Naldemedine is predicted to bind to 3CLpro encoded by SARS-CoV2 genome.
